Kerala, WB Used ‘Extra Dose’, Reported Negative Vax Wastage

New Delhi : Exemplary performance by Kerala and West Bengal which recorded a negative (-6.3% and -5.4%) vaccine wastage, saving 1.1 lakh and 1.6 lakh doses respectively, shows that optimum use and diligent supply management of vaccines is possible, said central government officials.

In fact, the two states reported negative wastage of Covid vaccines by making use of the “extra dose” available as a wastage factor in each vial.

Official data for May show Kerala and West Bengal standing in sharp contrast to states like Jharkhand and Chhattisgarh which recorded a high 33.9% and 15.7% wastage respectively. The wastage for other states is lower, but still on the higher side like in Madhya Pradesh (7.3%) and Punjab (7%). Doing better, but still short of the optimum 1% suggested by the Centre are Delhi (3.9%), Gujarat (3.6%), Rajasthan (3.9%) and UP (3.7%).

Government sources said the closing balance of shots with various states was 212 lakh. The month saw a poor rate of vaccination due to a switch to a new procurement system — since abandoned — and a fear of infection that kept people indoors. The closing balance of vaccines was less at 80 lakh in April. However, it was higher in February and March, with the latter marked by a misplaced sense of complacency that the infection had ebbed. This had resulted in vaccination slots going unutilised.

The first dose coverage of the 45-plus population stands at 38%, with Tamil Nadu, Jharkhand, Bihar and Assam lagging at sub- 30% levels. Better performing states include Rajasthan, Chhattisgarh, Gujarat and Karnataka.

Second dose coverage among front-line workers stands at 45%, with Rajasthan, Chhattisgarh, Bengal, Kerala and MP being the better performing states. First dose coverage is at 84%. Worryingly, second dose coverage for healthcare workers is only 56% while for first dose it is 81%.

  • Related Posts

    Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

    Mumbai: The Maharashtra FDA will prioritise process audits of drug manufacturing units across the state to assess compliance with the revised Schedule M requirements, with no exemption for pharmaceutical MSMEs,…

    Centre bans fixed-dose combination for Common Cold in children below four

    The ministry said the use of “Chlorpheniramine Maleate and Phenylephrine Hydrochloride” drug combination in children below four years could pose health risks, while their safer alternatives are available in the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

    Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

    Centre bans fixed-dose combination for Common Cold in children below four

    Centre bans fixed-dose combination for Common Cold in children below four

    New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

    New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

    Brain organoid maturation is driven by a lifelike developmental clock: Study

    Brain organoid maturation is driven by a lifelike developmental clock: Study

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy